Hims & Hers to Launch Generic Semaglutide in Canada in 2026
Hims & Hers Health, a U.S.-based telehealth platform, plans to enter the Canadian market in 2026, offering generic semaglutide drugs following the expiration of Novo Nordisk’s patents on Ozempic and Wegovy. This move marks the company’s first venture into Canada, aligning with its recent European expansion through the acquisition of Zava.
Strategic Expansion into Canada
Hims & Hers aims to capitalize on the growing demand for affordable weight loss treatments in Canada. Andrew Dudum, co-founder and CEO, emphasized the company’s goal to provide accessible, high-quality care: “Canada represents a significant opportunity to demonstrate affordable weight loss solutions, combining cost-effectiveness with trusted, personalized care.”
The Canadian semaglutide market, valued at $1.18 billion in 2024, is projected to grow to $4.03 billion by 2035, according to Grand View Research. Hims & Hers is partnering with an approved manufacturer to ensure compliance with Canadian regulations, though it has not confirmed whether it has filed for Health Canada approval for its generic semaglutide.
Novo Nordisk’s Patent Lapse
Novo Nordisk’s patent on semaglutide in Canada lapsed in 2020 due to non-payment of a maintenance fee, with the patent set to expire in January 2026. Documents from the Canadian Patent Database reveal that Novo Nordisk last paid the $250 annual fee in 2018 and requested a refund in 2017 to delay payment. A subsequent late fee of $450 was not paid within the one-year grace period, leading to the patent’s lapse. Canadian authorities noted that lapsed patents cannot be revived.
This development has opened the door for generic manufacturers like Hims & Hers and Sandoz, which has already applied for Health Canada approval for its generic semaglutide. Novo Nordisk’s spokesperson said that such lapses are part of the normal life cycle of pharmaceutical patents, with decisions on intellectual property being “carefully considered.”
Market Dynamics and Industry Implications
The expiration of Novo Nordisk’s patent comes as its weight loss drug Wegovy faces competition from Eli Lilly’s Zepbound in the U.S. Hims & Hers’ entry into Canada follows the termination of its collaboration with Novo Nordisk, which raised concerns over Hims’ promotion of compounded semaglutide alternatives. Unlike generics, compounded drugs are customized and differ from standard doses.
David Meinertz, general manager of Hims & Hers’ international business, highlighted the potential impact: “Affordable obesity treatment can strengthen Canada’s healthcare system and improve millions of lives.” The company’s focus on generics, which mirror the efficacy and safety of branded drugs like Ozempic and Wegovy, positions it to compete in a rapidly growing market.